Skip to content

Effect of ruprasidone on the clinical efficacy and serum BDNF level of early risperidone in the treatment of unresponsive first-episode schizophrenia

Effect of ruprasidone on the clinical efficacy and serum BDNF level of early risperidone in the treatment of unresponsive first-episode schizophrenia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048395
Enrollment
Unknown
Registered
2021-07-06
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Continued risperidone treatment group:Risperidone
Early dressing change intervention group:Early dressing change
Active drug clozapine control group:Cozapine

Sponsors

Huzhou Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.First episode schizophrenia (DSM-V); 2.Aged 16 to 40 years; 3.First onset psychotic symptoms occurred before 36 years old, and the baseline PANSS total score was >= 60.

Exclusion criteria

Exclusion criteria: 1.Patients with organic mental disorder, affective mental disorder and other mental disorders; 2.Severe somatic diseases or disorders that may interfere with assessment such as defined obesity, eating disorders, diabetes, hypertension and heart disease; 3.Patients have substance abuse or dependence in recent one year; 4.Pregnant or lactating women; 5.Intelligence before illness, IQ <= 70.

Design outcomes

Primary

MeasureTime frame
Positive and negative psychiatric symptom rating scale;Global assessment of function score;Treatment emergent symptom scale;Serum brain-derived neurotrophic factor;

Countries

China

Contacts

Public ContactHuang Guangbiao

Huzhou Third People's Hospital

29066039@qq.com+86 18805823906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026